TABLE 3.
Dose Ratiosa | ||||||
---|---|---|---|---|---|---|
Days after nor-BNI |
i.c. nor-BNI 0.32 mg | i.c. nor-BNI 0.032 mg | s.c. nor-BNI 0.32 mg | |||
versus U50,488 |
versus bremazocine |
versus U50,488 |
versus bremazocine |
versus U50,488 |
versus bremazocine |
|
1 | 9.5* | 3.0* | 1.0 | |||
3 | 1.8 | 0.9 | 1.0 | |||
7 | 7.5* | 2.5* | 1.2 | |||
10 | 1.9 | 0.8 | 1.0 | |||
14 | 3.9* | 1.0 | ||||
21 | 7.9* | 0.8 | ||||
28 | 2.0 | 1.0 | ||||
35 | 5.4* | 0.7 | ||||
42 | 0.7 | |||||
49 | 1.5 | |||||
56 | 1.0 | |||||
63 | 1.0 |
Dose ratios were mean of individual dose ratio values (n = 4).
Significant rightward shift of dose-effect curve *p < .05.